双歧杆菌三联活菌胶囊与利福昔明治疗肠易激综合征合并小肠细菌过度生长临床效果比较  

Clinical effect comparison between Bifidobacterium triple viable capsules and Rifaximin on irritable bowel syndrome with small intestinal bacterial overgrowth

作　　者：王晓辉[1] 闫志辉[1] 李超[1] 贺星[1] 弓三东 崔立红[1] 

机构地区：[1]海军总医院消化内科,北京100048

出　　处：《解放军医学院学报》2015年第10期970-972,975,共4页Academic Journal of Chinese PLA Medical School

基　　金：吴阶平临床科研专项资助基金(320.6750.13175)~~

摘　　要：目的研究益生菌对肠易激综合征(irritable bowel syndrome,IBS)合并小肠细菌过度生长(small intestinal bacterial overgrowth,SIBO)的治疗效果。方法选择2012年1月-2013年8月我院诊断的IBS患者100例为研究对象,男性38例,女性62例,年龄(44.7±8.1)岁。所有患者均完成甲烷-氢呼气试验,将64例阳性者随机分为抗生素组(22例,利福昔明治疗)、微生态组(21例,双岐杆菌三联活菌胶囊治疗)及安慰剂组(21例,安慰剂治疗),比较3组患者治疗前后临床症状积分、小肠细菌过度生长转阴率、治疗有效率之间的差异。结果抗生素组(11.39±3.67 vs 4.96±1.19)与微生态组(11.38±3.46 vs 4.89±1.17)治疗前后的临床症状积分均明显改善(P<0.001);微生态组治疗后临床症状积分(4.89±1.17)、总有效率(85.71%)及SIBO转阴率(71.43%)与抗生素组(4.96±1.19,86.36%,72.73%)差异无统计学意义(P>0.05);抗生素组、微生态组治疗后临床症状积分、总有效率及转阴率与安慰剂组治疗后(10.23±3.43,28.57%,9.50%)差异均有统计学意义(P<0.05)。结论双歧杆菌三联活菌胶囊与利福昔明疗效同样确切,微生态制剂可以广泛用于IBS合并SIBO的治疗。Objective To observe the clinical effect of probiotics on irritable bowel syndrome（IBS） with small intestinal bacterial overgrowth（SIBO） and provide basis for the application of probiotics in IBS treatment. Methods From January 2012 to August 2013, 100 IBS patients（38 males and 62 females with an average age of 44.7±8.1 years） were chosen as research object in our hospital. According to the result of methane-hydrogen breath test, 64 SIBO patients were divided into 3 groups randomly（antibiotics group, probiotics group and placebo group） and received treatment with rifaximin, Bifidobacterium triple viable capsules and placebo separately. After treatment, the difference of their clinical symptom score, SIBO negative rate and treatment efficiency were compared. Results Compared with the integral before treatment, the clinical symptom integral of antibiotics group（11.39±3.67 vs 4.96±1.19） and probiotics group（11.38±3.46 vs 4.89±1.17） decreased significantly, their difference had statistical significance（P〈 0.001）. Compared with antibiotics group（4.96±1.19, 86.36%, 72.73%）, the clinical symptom integral（4.89±1.17）, treatment efficiency（85.71%） and negative rate（71.43%） in probiotics group had no statistical significance（P〉 0.05）. Compared with placebo group（10.23±3.43, 28.57%, 9.50%）, the clinical symptom integral, treatment efficiency and negative rate of antibiotics group and probiotics group had statistical significance（P〈 0.05）. Conclusion Bifidobacterium triple viable capsules has the same clinical effect with rifaximin. Probiotics can be widely used in the treatment of IBS with SIBO.

关 键 词：双歧杆菌三联活菌胶囊 利福昔明 肠易激综合征 小肠细菌过度生长 

分 类 号：R574[医药卫生—消化系统]